Atalaya Capital Management’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Atalaya Capital Management’s Portfolio EBACW Stock Details EBACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,333	Closed	-$3.33K	–	295
2022 Q4	$3.33K	Hold	13,333	–	–	﹤0.01%	238
2022 Q3	$1K	Hold	13,333	–	–	﹤0.01%	372
2022 Q2	$2K	Hold	13,333	–	–	﹤0.01%	331
2022 Q1	$3K	Hold	13,333	–	–	﹤0.01%	390
2021 Q4	$8K	Hold	13,333	–	–	﹤0.01%	392
2021 Q3	$8K	Hold	13,333	–	–	﹤0.01%	327
2021 Q2	$13K	Buy	+13,333	New	+$12.4K	﹤0.01%	303

Atalaya Capital Management's EBACW Position: Q1 2023 in Review

Atalaya Capital Management sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q1 2023, closing a stake of 13,333 shares — an estimated $3.33K sold.

Atalaya Capital Management first reported a position in EBACW in Q2 2021 and held it in 7 quarters. The position peaked at $13K in Q2 2021. 0 funds tracked by Wall St. Rank hold EBACW as of Q1 2023.

Atalaya Capital Management reported no remaining European Biotech Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
Atalaya Capital Management sold 13,333 European Biotech Acquisition Corp. Warrant shares in Q1 2023, an estimated $3.33K.
Atalaya Capital Management first reported a position in European Biotech Acquisition Corp. Warrant in Q2 2021 and held it in 7 quarters.
Atalaya Capital Management's European Biotech Acquisition Corp. Warrant position peaked at $13K in Q2 2021.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q1 2023.

Based on Atalaya Capital Management's 13F filing for Q1 2023, filed 11 May 2023.